Herriot Tabuteau Sells 78,703 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CEO Herriot Tabuteau sold 78,703 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $171.28, for a total value of $13,480,249.84. Following the completion of the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at approximately $1,238,183.12. The trade was a 91.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Herriot Tabuteau also recently made the following trade(s):

• On Tuesday, January 6th, Herriot Tabuteau sold 29,450 shares of Axsome Therapeutics stock. The shares were sold at an average price of $172.33, for a total value of $5,075,118.50.
• On Wednesday, January 7th, Herriot Tabuteau sold 31,261 shares of Axsome Therapeutics stock. The shares were sold at an average price of $170.38, for a total transaction of $5,326,249.18.
• On Thursday, December 4th, Herriot Tabuteau sold 10,558 shares of Axsome Therapeutics stock. The stock was sold at an average price of $148.18, for a total transaction of $1,564,484.44.
• On Tuesday, December 2nd, Herriot Tabuteau sold 49,252 shares of Axsome Therapeutics stock. The shares were sold at an average price of $144.59, for a total transaction of $7,121,346.68.
• On Wednesday, December 3rd, Herriot Tabuteau sold 20,163 shares of Axsome Therapeutics stock. The stock was sold at an average price of $146.94, for a total transaction of $2,962,751.22.
• On Tuesday, November 4th, Herriot Tabuteau sold 50,459 shares of Axsome Therapeutics stock. The stock was sold at an average price of $133.79, for a total transaction of $6,750,909.61.
• On Wednesday, November 5th, Herriot Tabuteau sold 21,775 shares of Axsome Therapeutics stock. The shares were sold at an average price of $134.49, for a total transaction of $2,928,519.75.
• On Monday, November 3rd, Herriot Tabuteau sold 91,705 shares of Axsome Therapeutics stock. The stock was sold at an average price of $132.34, for a total value of $12,136,239.70.

Axsome Therapeutics Stock Performance

AXSM stock opened at $167.55 on Friday. The firm has a market cap of $8.45 billion, a PE ratio of -35.88, a price-to-earnings-growth ratio of 9.00 and a beta of 0.44. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66. The stock has a 50-day moving average price of $150.22 and a 200-day moving average price of $127.35. Axsome Therapeutics, Inc. has a 1-year low of $79.19 and a 1-year high of $184.40.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.12). The business had revenue of $170.99 million for the quarter, compared to the consensus estimate of $162.96 million. Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The business’s revenue for the quarter was up 63.2% on a year-over-year basis. As a group, equities research analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Hedge Funds Weigh In On Axsome Therapeutics

Hedge funds have recently modified their holdings of the company. Wellington Management Group LLP boosted its stake in shares of Axsome Therapeutics by 84.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock worth $162,082,000 after buying an additional 609,516 shares during the last quarter. Norges Bank bought a new stake in Axsome Therapeutics during the second quarter worth $48,889,000. Invesco Ltd. boosted its position in Axsome Therapeutics by 73.3% in the third quarter. Invesco Ltd. now owns 990,557 shares of the company’s stock worth $120,303,000 after purchasing an additional 419,008 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its stake in Axsome Therapeutics by 831.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 447,000 shares of the company’s stock valued at $46,662,000 after purchasing an additional 399,000 shares during the period. Finally, Hood River Capital Management LLC purchased a new stake in shares of Axsome Therapeutics during the 2nd quarter valued at $38,740,000. Institutional investors own 81.49% of the company’s stock.

Analysts Set New Price Targets

AXSM has been the topic of several research analyst reports. UBS Group increased their target price on shares of Axsome Therapeutics from $163.00 to $248.00 and gave the stock a “buy” rating in a research note on Tuesday. Morgan Stanley cut shares of Axsome Therapeutics from an “overweight” rating to a “reduce” rating in a research report on Thursday. HC Wainwright boosted their target price on Axsome Therapeutics from $185.00 to $200.00 and gave the company a “buy” rating in a research report on Monday. Needham & Company LLC reaffirmed a “buy” rating and issued a $225.00 target price on shares of Axsome Therapeutics in a research report on Monday. Finally, Mizuho set a $217.00 price target on Axsome Therapeutics in a report on Wednesday, December 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Axsome Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $192.35.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised its 2026 earnings estimates (Q2/Q3/Q4 and FY2026 to a combined $3.72 EPS) and reiterated a Buy with a $200 price objective, signaling expectations for stronger near‑term profitability and supporting higher valuation.
• Positive Sentiment: UBS reiterated its Buy rating on AXSM, reinforcing institutional analyst support that can help underpin demand for the shares. Read More.
• Positive Sentiment: Market commentary points to late‑2025 FDA moves — acceptance of a supplemental filing for AXS‑05 (agitation in Alzheimer’s) and FDA support for an NDA filing for AXS‑12 (narcolepsy) — expanding potential indications and revenue runway. Read More.
• Neutral Sentiment: Morgan Stanley reaffirmed an “equal weight” view but lifted its price target to $204 (from $196), implying upside vs. current levels but stopping short of a buy endorsement. Read More.
• Negative Sentiment: Insider selling: CEO Herriot Tabuteau sold a large block of shares across Jan. 5–7 (totaling roughly 139,414 shares over multiple transactions), leaving him with ~7,229 shares — a >90% reduction in his direct holding. Large, concentrated CEO sales can create near‑term supply pressure and raise investor concerns about optics or liquidity needs. Read More.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.